US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

335.88

+24.267.79%

Number of Gainers:5

Number of Losers:- -

Number of Flat:- -

PE:- -

High:341.69

Open:314.28

Low:314.26

Close:311.66

Loading ...

Crispr Therapeutics call volume above normal and directionally bullish

Bernstein Remains a Buy on Intellia Therapeutics (NTLA)

Editas Medicine Inc. EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares

Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data

Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment

Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning

THOMSON REUTERS

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS

Editas Medicine Inc. Conducted Annual Stockholders Meeting

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

THOMSON REUTERS

Press Release: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares

Beam Therapeutics treatment of sickle cell disease granted orphan designation

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

THOMSON REUTERS

Press Release: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":335.91946,"timestamp":1749236825071,"preClose":311.65695,"halted":0,"volume":19208805,"delay":0,"changeRate":0.07785,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":24.262512,"latestTime":"06-06 15:07:07 EDT","open":314.28003,"high":341.68842,"low":314.2557,"amount":253752556.281717,"amplitude":0.088022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749240000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.584867,"peRate":-3.695256,"turnoverRate":0.032722,"increases":5,"decrements":0,"flats":0,"marketCap":6567622872,"floatMarketCap":6327520696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":341.68842,"amplitude":0.088022,"preClose":311.65695,"low":314.2557,"pbRate":"1.584867","latestPrice":335.8753,"volume":19208932,"delay":0,"open":314.28003,"prevYearClose":376.62552,"prevWeekClose":291.1356,"prevMonthClose":291.1356,"prevQuarterClose":297.7814,"fiveDayClose":291.1356,"twentyDayClose":306.2187,"sixtyDayClose":394.0621,"secType":"PLATE","market":"US","turnoverRate":0.032722,"peRate":-3.695256,"marketCap":6566759384,"floatMarketCap":6326661304,"timestamp":1749236829088,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541070669","title":"Crispr Therapeutics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2541070669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541070669?lang=en_us&edition=fundamental","pubTime":"2025-06-06 01:25","pubTimestamp":1749144318,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Crispr Therapeutics (CRSP) with 6,908 calls trading, 3x expected, and implied vol increasing almost 4 points to 63....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","CRSP","BK4556","LENZ","BK4539","BK4588","BK4139","BK4585","BK4007","LU1861559042.SGD","LU1861558580.USD"],"gpt_icon":0},{"id":"2541077197","title":"Bernstein Remains a Buy on Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2541077197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541077197?lang=en_us&edition=fundamental","pubTime":"2025-06-06 00:55","pubTimestamp":1749142531,"startTime":"0","endTime":"0","summary":"Bernstein analyst William Pickering maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $14.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-buy-on-intellia-therapeutics-ntla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-buy-on-intellia-therapeutics-ntla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","BK4535","LU1861558580.USD","BK4585","BK4139","BK4588","BK4556","NTLA"],"gpt_icon":0},{"id":"2541092842","title":"Editas Medicine Inc. EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092842","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092842?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:38","pubTimestamp":1749076703,"startTime":"0","endTime":"0","summary":"Linda Burkly, EVP, Chief Scientific Officer at Editas Medicine Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL2NGbg5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"gpt_icon":0},{"id":"2541409284","title":"Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541409284","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541409284?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:37","pubTimestamp":1749076631,"startTime":"0","endTime":"0","summary":"Neil O'Neill Gilmore, the CEO and Director of Editas Medicine Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL7gH0cq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"gpt_icon":0},{"id":"2541509375","title":"How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541509375","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541509375?lang=en_us&edition=fundamental","pubTime":"2025-06-04 21:55","pubTimestamp":1749045309,"startTime":"0","endTime":"0","summary":"Shares of Intellia Therapeutics, Inc.  have gained 6.1% over the past four weeks to close the last trading session at $7.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $38.32 indicates a potential upside of 398.3%.However, an impressive consensus price target is not the only factor that indicates a potential upside in NTLA. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/much-upside-left-intellia-therapeutics-135509183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4588","LU1861559042.SGD","BK4139","BK4556","LU1861558580.USD","NTLA","BK4585"],"gpt_icon":0},{"id":"2541093732","title":"Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2541093732","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541093732?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:55","pubTimestamp":1749041700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics is currently evaluating two in vivo candidates, namely CTX310 and CTX320, in separate early-stage studies, targeting ANGPTL3 and lipoprotein [Lp], respectively — both associated with atherosclerotic heart disease.Last month, CRSP reported initial top-line data from the first 10 patients acrossthe first four cohorts of the phase I study on CTX310. A single dose demonstrated dose-dependent decreases in low-density lipoprotein  and triglyceride  levels, with peak reduction of up to 82% in TG and up to 81% in LDL.These results have raised excitement around CTX320, a readout from which is expected later in the second quarter of 2025. CRISPR Therapeutics also intends to advance two additional in vivo programs into the clinic by year-end, further expanding its footprint in this emerging modality.The company is currently lagging behind Intellia TherapeuticsNTLA, which is one of the few companies with multiple clinical-stage in vivo gene editing programs. Intellia is advanci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-build-casgevys-success-vivo-125500765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","HAE","LU0205194284.USD","LU1169589451.USD","BK4556","CRSP","IE00BLDYK493.USD","BK4153","LDL","IE00B64QTZ34.USD","TG","BK4090","BK4611","NTLA","LU1169590202.USD","BK4585","LU1861559042.SGD","BK4588","BGSX","LU0012050646.USD","LU0205193047.USD","LU1861558580.USD","BK4139","LU0106261612.USD","BEAM","BK4535","BK4505"],"gpt_icon":0},{"id":"2540803826","title":"Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2540803826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540803826?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:01","pubTimestamp":1748955660,"startTime":"0","endTime":"0","summary":"New Patent Positions DrivebuddyAI to Lead India’s Upcoming Road Safety Mandates, Achieves 72% Accident Reduction Across Fleets. NEW YORK, June 03, 2025  -- Roadzen Inc.  , a global leader in AI at the intersection of insurance and mobility, today announced that its DrivebuddyAI platform has been granted a patent in India for its Real-Time Driver Drowsiness Detection Algorithm.DrivebuddyAI’s patented system leverages AI and computer vision to monitor over 92 real-time eye and facial cues, enabling early detection of driver fatigue and triggering instant alerts—helping prevent accidents before they occur. The newly granted patent strengthens Roadzen’s expanding global IP portfolio, with additional filings underway in the U.S. and Europe.According to the U.S. National Highway Traffic Safety Administration , crashes involving at least one distracted driver accounted for 29% of all motor vehicle crashes and costs. This underscores the urgent need for real-time safety technologies like Drive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roadzen-drivebuddyai-awarded-patent-real-130100836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4556","BK4131","BK4611","CARD","BK4585","BK4505","BK4535","BEAM","RDZNW","ARAI","BK4139"],"gpt_icon":0},{"id":"2540927775","title":"Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540927775","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540927775?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948435,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., June 03, 2025 - Beam Therapeutics Inc.  announced that the U.S. Food and Drug Administration  has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for treating sickle cell disease . This designation underscores the critical need for innovative treatments for SCD, a debilitating disorder affecting approximately 100,000 people in the U.S. BEAM-101, the lead program in Beam's hematology franchise, has shown promise in clinical trials, demonstrating significant increases in fetal hemoglobin and reductions in sickle hemoglobin among patients. The FDA's orphan drug designation offers potential benefits, including tax credits for clinical trials and a possible seven years of market exclusivity post-approval. Beam Therapeutics continues to advance its BEACON Phase 1/2 clinical trial, with plans to dose 30 patients by mid-2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL4MCqP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","BEAM","IE00BGHQF748.EUR","BK4556","BK4139","BK4585","IE00BKPKM429.USD","BK4505","BK4611","BK4535","NDAQ","IE00B64PRP62.GBP","BK4588","BK4112"],"gpt_icon":0},{"id":"2540775947","title":"Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2540775947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540775947?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA3CKJQ9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4588","BK4556","BK4611","BK4535","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"2540577531","title":"Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2540577531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540577531?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA3CKJQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","BK4588","BK4585","BEAM","BK4535","BK4505","BK4611"],"gpt_icon":0},{"id":"2540837716","title":"Editas Medicine Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540837716","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540837716?lang=en_us&edition=fundamental","pubTime":"2025-06-03 05:29","pubTimestamp":1748899780,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. During the meeting, stockholders elected Jessica Hopfield, Ph.D., and David Scadden, M.D., as Class III directors. Additionally, stockholders approved an amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of capital stock and common stock. An amendment and restatement of the 2015 Stock Incentive Plan was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLbk5C5y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","EDIT"],"gpt_icon":0},{"id":"2540798498","title":"bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798498?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:34","pubTimestamp":1748867640,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUAC46HXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4578","BLUE","BK4139"],"gpt_icon":0},{"id":"2540244798","title":"Press Release: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2540244798","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540244798?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:34","pubTimestamp":1748867640,"startTime":"0","endTime":"0","summary":"New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies. Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access. bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers. David Meek, who became Chief Executive Officer of bluebird at close, said, \"Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies.\". The company's momentum is reinforced by a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLUE","BK4578","IE00B64PRP62.GBP","BK4139","CG","BK4556","IE00BGHQF748.EUR","BK4135","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2540760986","title":"The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760986","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760986?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:45","pubTimestamp":1748864700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing.Regeneron's biggest growth driver is still performing well, and it is developing newer medicines.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/the-2-smartest-beaten-down-biotech-stocks-to-buy-o/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4534","LU0943347566.SGD","LU2756315664.SGD","BK4083","LU0820562030.AUD","LU0820561909.HKD","LU0320765646.SGD","LU0354030438.USD","LU1778281490.HKD","LU1861558580.USD","BK4504","LU1093756325.SGD","BK4581","LU0823411888.USD","LU1069344957.HKD","HD","LU1551013425.SGD","LU1989772840.SGD","LU0079474960.USD","BK4566","SCD","IE00B1XK9C88.USD","CRSP","LU0868494708.USD","LU0823434583.USD","IE00BWXC8680.SGD","BK4585","LU1551013342.USD","LU0823434740.USD","LU1496350502.SGD","BK4611","IE00BZ1G4Q59.USD","BK4588","LU1162221912.USD","LU1674673428.USD","SG9999001440.SGD","BK4567","BK4533","LU0868494617.USD","IE00BSNM7G36.USD","LU0689472784.USD","LU1861559042.SGD","BK4556","LU0354030511.USD","LU1989772923.USD","BK4139","LU1674673691.USD","LU2756315318.SGD","LU1496350171.SGD","LU0234572021.USD"],"gpt_icon":0},{"id":"2539717208","title":"CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539717208","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539717208?lang=en_us&edition=fundamental","pubTime":"2025-05-31 05:00","pubTimestamp":1748638848,"startTime":"0","endTime":"0","summary":"Naimish Patel, Chief Medical Officer, reported a disposal of common shares of CRISPR Therapeutics AG. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL7pzfcd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4588","BK4556","BK4585","CRSP","BK4611","BK4139","LU1861559042.SGD"],"gpt_icon":0},{"id":"2539277510","title":"Beam Therapeutics treatment of sickle cell disease granted orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2539277510","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539277510?lang=en_us&edition=fundamental","pubTime":"2025-05-31 03:00","pubTimestamp":1748631615,"startTime":"0","endTime":"0","summary":"The FDA granted orphan designation to a treatment of sickle cell disease being developed by Beam Therapeutics (BEAM), according to a post to the ag...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-sickle-cell-disease-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-sickle-cell-disease-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BEAM","BK4139","BK4556","BK4588","BK4611","BK4007","BK4539","BK4585","BK4535","BK4505"],"gpt_icon":0},{"id":"2539220892","title":"Sector Update: Health Care Stocks Fall Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2539220892","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539220892?lang=en_us&edition=fundamental","pubTime":"2025-05-30 21:17","pubTimestamp":1748611073,"startTime":"0","endTime":"0","summary":"Health care stocks were falling pre-bell Friday as the Health Care Select Sector SPDR Fund  was down 0.4% and the iShares Biotechnology ETF  was 1.4% lower recently.Sanofi  and Regeneron Pharmaceuticals  said one of the phase 3 trials of itepekimab in adults who were former smokers with inadequately controlled chronic obstructive pulmonary disease, or COPD, met its primary endpoint while another did not meet the same primary endpoint. Shares of Sanofi were down more than 4% while Regeneron shares were more than 13% lower premarket.Cooper  shares were down more than 8% even after the company reported higher fiscal Q2 non-GAAP earnings and net sales.Beam Therapeutics  shares were advancing by more than 3% after the company said the US Food and Drug Administration granted orphan drug designation to BEAM-302.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","LU0053666078.USD","LU2272731782.SGD","XLV","BK4139","LU0320765992.SGD","COO.AU","LU1917777945.USD","LU1974910355.USD","LU2211815571.USD","LU2362540622.SGD","BK4535","LU0289739699.SGD","LU0823434583.USD","LU0889565916.HKD","LU0114720955.EUR","BK4556","LU0823416689.USD","BK4007","LU1992135399.USD","LU0109394709.USD","LU1992135472.HKD","LU0058720904.USD","BEAM","SNY","IBB","IE00BFXG1179.USD","BK4588","LU0823434740.USD","BK4585","GB00BDT5M118.USD","LU2023250504.SGD","LU2106854487.HKD","BK4581","COO","LU2089984988.USD","LU2468319806.SGD","BK7016","BK4198","LU0882574055.USD","LU2362541273.HKD","LU2237438978.USD","LU2362541513.USD","BK4505","LU2272731600.USD","BK4611"],"gpt_icon":0},{"id":"2539226932","title":"Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226932?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:30","pubTimestamp":1748608200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA59W9VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","CG","BK4139","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4556","BLUE","BK4135","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2539222635","title":"Press Release: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222635?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:30","pubTimestamp":1748608200,"startTime":"0","endTime":"0","summary":"All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025. Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade--first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","IE00B3QW5Z07.USD","CG","IE00BGHQF748.EUR","BK4578","BLUE","BK4135","BK4556"],"gpt_icon":0},{"id":"2539223844","title":"Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2539223844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539223844?lang=en_us&edition=fundamental","pubTime":"2025-05-30 17:57","pubTimestamp":1748599030,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-intellia-therapeutics-despite-mild-adverse-event-in-phase-3-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-intellia-therapeutics-despite-mild-adverse-event-in-phase-3-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","LU0149725797.USD","LU0070302665.USD","LU1267930573.SGD","LU0971096721.USD","LU0106831901.USD","LU0128525929.USD","LU0289960550.SGD","LU0320765489.SGD","LU1267930227.SGD","LU0314106906.USD","LU2461242641.AUD","LU2361045086.USD","LU2361044949.HKD","LU0310800379.SGD","LU1267930490.SGD","LU1280957306.USD","LU0683600562.USD","LU1035773651.USD","LU1814569148.SGD","LU0267386448.USD","LU0154236417.USD","LU0708994859.HKD","LU0310799852.SGD","BK4559","LU1861559042.SGD","BK4556","LU1668664300.SGD","LU1861558580.USD","BK4585","LU0072461881.USD","BK4535","LU1074936037.SGD","LU0980610538.SGD","LU0310800965.SGD","LU0477156953.USD","LU0130102774.USD","BK4207","LU0251131958.USD","LU0251142724.SGD","LU1069347547.HKD","LU0648001328.SGD","LU1201861249.SGD","LU0128525689.USD","LU0029864427.USD","LU0211327993.USD","IE0002270589.USD","LU0640476718.USD","BK4501","NTLA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}